Wave Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update
“Since the start of the year, we have made significant progress advancing suvodirsen, our lead clinical program for the treatment of Duchenne muscular dystrophy patients amenable to exon 51 skipping, and we look forward to providing dystrophin biopsy data in the second half of the year. In parallel, initial commercialization activities are underway to support the potential approval and launch of this investigational therapy, first in
Wave is committed to building a fully integrated genetic medicines company led by its clinical- and preclinical-stage programs for the treatment of neuromuscular, central nervous system and ophthalmologic diseases.
Initial commercialization activities ongoing following completion of suvodirsen Phase 1 clinical trial; efficacy data from ongoing open-label extension study expected this year
April 2019, Wave announced the final results from its Phase 1 clinical trial of investigational suvodirsen (WVE-210201) in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. The results demonstrated a favorable safety and tolerability profile of suvodirsen for continued clinical development in the ongoing open-label extension (OLE) study and planned Phase 2/3 clinical trial.
- Suvodirsen is currently being studied in an OLE study, initiated in
August 2018with patients from the Phase 1 clinical trial. Wave expects to deliver an interim analysis of dystrophin expression from muscle biopsies in boys receiving suvodirsen in this study in the second half of 2019.
- The company expects to file for an accelerated approval of suvodirsen in
the United Statesin the second half of 2020, pending positive clinical dystrophin expression data.
DYSTANCE 51, Wave’s Phase 2/3 clinical trial of suvodirsen in DMD, intended to support global regulatory filings
April 2019, Wave announced the design of DYSTANCE 51, the planned Phase 2/3 efficacy and safety clinical trial of suvodirsen. The trial is designed to enroll boys who are between 5 and 12 years of age (inclusive) with a genetically confirmed diagnosis of DMD amenable to exon 51 skipping therapy. The DYSTANCE 51 primary efficacy endpoints will measure change in dystrophin protein level and change in the North Star Ambulatory Assessment score. In addition, the trial will include multiple functional outcome measures as secondary efficacy endpoints.
January 2019, the company announced that DYSTANCE 51 was selected for the U.S. Food and Drug Administration( FDA) complex innovative trial designs pilot program. Through this program, Wave intends to reduce the number of patients required to deliver conclusive clinical efficacy results, thereby minimizing the number of patients required in the placebo treatment arm and potentially accelerating study completion. Through participation in the program, the company has met with FDAstaff to discuss design elements of the trial.
- DYSTANCE 51 is expected to be initiated in
July 2019and the company intends to use the results of this trial to seek regulatory approvals globally.
Aiming to bring meaningful dystrophin protein restoration to more patients living with DMD
- Wave is leveraging learnings from its ongoing DMD development and discovery efforts to advance WVE-N531, its preclinical candidate to treat DMD in boys amenable to exon 53 skipping. WVE-N531 induced up to 71% dystrophin protein restoration in DMD in vitro patient-derived myoblasts compared with healthy human myoblasts as measured by western blot. Subject to submission of clinical trial applications and approval to proceed, Wave expects to deliver topline clinical data for WVE‑N531 in the second half of 2020.
- The company is also exploring exon targets beyond those targeted by suvodirsen and WVE-N531, including exons 44, 45, 52, 54 and 55.
Central Nervous System (CNS) Diseases
Advancing PRECISION-HD clinical program, the first allele-selective approach for Huntington’s disease patients
- Wave’s PRECISION-HD program, which consists of two global Phase 1b/2a clinical trials evaluating investigational therapies WVE-120101 and WVE-120102 for patients with
Huntington'sdisease (HD), is continuing to enroll patients globally. The company expects to report topline clinical data from the PRECISION-HD program by the end of the year. These results are expected to include a summary of clinical safety results, the degree of mutant huntingtin protein lowering in cerebrospinal fluid (CSF) and the ratio of total huntingtin versus mutant huntingtin protein in CSF to assess wild-type huntingtin protein.
- WVE-120101 and WVE-120102, which selectively target the mutant allele of the huntingtin (HTT) gene, have been shown to reduce levels of mutant HTT mRNA and protein, while leaving wild-type or healthy HTT mRNA and protein largely intact in in vitro studies with patient-derived cell-lines. The healthy transcript is required to produce healthy HTT protein which is critical for neuronal function. Multiple preclinical studies in the literature indicate that long-term suppression of healthy HTT protein may have detrimental consequences. Wave’s allele-specific approach may also enable the company to address the pre-manifest, or asymptomatic, HD patient population in the future.
Leveraging PRISM to optimize C9ORF72 program and potential future CNS candidates
- Wave announced today that it has further optimized its C9ORF72-targeting program in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (
FTD) and is advancing a new lead candidate (WVE-C092), which preferentially targets the transcript containing the GGGGCC (G4C2) expansion in the C9ORF72 gene. The company leveraged advances in PRISM, its discovery and drug development platform, to design a candidate with an improved profile, including a substantial increase in potency in a preclinical study over its prior lead candidate. The observed potency and the expected durability of WVE-C092 may allow dosing frequency to be substantially optimized.
- Subject to the submission of clinical trial applications and approval to proceed, the company would expect to initiate clinical development of WVE-C092 in the second half of 2020.
- The company is utilizing the learnings from PRISM to design additional stereopure oligonucleotides with optimized profiles across other CNS diseases as part of its ongoing collaboration with Takeda.
- Wave continues to advance stereopure oligonucleotides for the potential treatment of inherited retinal diseases. Preclinical data demonstrated that a single intravitreal injection of stereopure oligonucleotide in the eye of non-human primates resulted in greater than 95% knockdown of a target RNA in the retina for at least four months. Based on these data, the company is working to design clinical candidates that could achieve a therapeutic effect with only two doses per year. The company expects to announce its first ophthalmology candidate in the second half of 2019.
First Quarter 2019 Financial Results and Financial Guidance
Wave reported a net loss of
Research and development expenses were
General and administrative expenses were
Wave expects that its existing cash and cash equivalents, together with expected and committed cash from existing collaborations, will enable Wave to fund its operating and capital expenditure requirements to the end of 2020.
PRISM is Wave Life Sciences’ proprietary discovery and drug development platform that enables genetically defined diseases to be targeted with stereopure oligonucleotides across multiple therapeutic modalities. PRISM combines the company’s unique ability to construct stereopure oligonucleotides with a deep understanding of how the interplay among oligonucleotide sequence, chemistry and backbone stereochemistry impacts key pharmacological properties. By exploring these interactions through iterative analysis of in vitro and in vivo outcomes and artificial intelligence-driven predictive modeling, the company continues to define design principles that are deployed across programs to rapidly develop and manufacture clinical candidates that meet pre-defined product profiles.
This press release contains forward-looking statements concerning our goals, beliefs, expectations, strategies, objectives and plans, and other statements that are not necessarily based on historical facts, including statements regarding the following, among others: the anticipated commencement, patient enrollment, data readouts and completion of our clinical trials, and the announcement of such events; the protocol, design and endpoints of our ongoing and planned clinical trials; the future performance and results of our programs in clinical trials; future preclinical activities and programs; the progress and potential benefits of our collaborations with partners; the potential of our in vitro and in vivo preclinical data to predict the behavior of our compounds in humans; our identification of future candidates and their therapeutic potential; the anticipated therapeutic benefits of our potential therapies compared to others; our ability to design compounds using multiple modalities and the anticipated benefits of that model; the anticipated benefits of our proprietary manufacturing processes and our internal manufacturing facility; our future growth and anticipated transition to a fully integrated commercial-stage company; the potential benefits of PRISM and our stereopure oligonucleotides compared with stereorandom oligonucleotides; the benefit of nucleic acid therapeutics generally; the strength of our intellectual property; and the anticipated duration of our cash runway. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including the following: our ability to finance our drug discovery and development efforts and to raise additional capital when needed; the ability of our preclinical programs to produce data sufficient to support our clinical trial applications and the timing thereof; our ability to continue to build and maintain the company infrastructure and personnel needed to achieve our goals; the clinical results of our programs, which may not support further development of product candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; our effectiveness in managing future clinical trials and regulatory processes; the effectiveness of PRISM; the continued development and acceptance of oligonucleotides as a class of medicines; our ability to demonstrate the therapeutic benefits of our candidates in clinical trials, including our ability to develop candidates across multiple therapeutic modalities; our dependence on third parties, including contract research organizations, contract manufacturing organizations, collaborators and partners; our ability to manufacture or contract with third parties to manufacture drug material to support our programs and growth; our ability to obtain, maintain and protect intellectual property; our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties; and competition from others developing therapies for similar uses, as well as the information under the caption “Risk Factors” contained in our most recent Annual Report on Form 10-K filed with the
UNAUDITED CONSOLIDATED BALANCE SHEETS
(In thousands, except share amounts)
|March 31, 2019||December 31, 2018|
|Cash and cash equivalents||$||287,567||$||174,819|
|Current portion of accounts receivable||10,000||10,000|
|Prepaid expenses and other current assets||17,464||17,454|
|Total current assets||315,031||202,273|
|Accounts receivable, net of current portion||50,000||50,000|
|Property and equipment, net||39,929||39,931|
|Operating lease right-of-use assets||19,333||—|
|Total long-term assets||115,581||93,667|
|Liabilities, Series A preferred shares and shareholders’ equity|
|Accrued expenses and other current liabilities||8,490||14,736|
|Current portion of deferred rent||—||115|
|Current portion of deferred revenue||105,891||100,945|
|Current portion of lease incentive obligation||—||1,156|
|Current portion of operating lease liability||2,919||—|
|Total current liabilities||131,877||130,041|
|Deferred rent, net of current portion||—||5,132|
|Deferred revenue, net of current portion||60,184||68,156|
|Lease incentive obligation, net of current portion||—||9,247|
|Operating lease liability, net of current portion||31,782||—|
|Total long-term liabilities||94,005||84,677|
|Series A preferred shares, no par value; 3,901,348 shares issued and
outstanding at March 31, 2019 and December 31, 2018
|Ordinary shares, no par value; 34,255,406 and 29,472,197 shares issued
and outstanding at March 31, 2019 and December 31, 2018, respectively
|Additional paid-in capital||42,113||37,768|
|Accumulated other comprehensive income||250||153|
|Total shareholders’ equity||$||196,856||$||73,348|
|Total liabilities, Series A preferred shares and shareholders’ equity||$||430,612||$||295,940|
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share amounts)
|Three Months Ended March 31,|
|Research and development||40,113||29,196|
|General and administrative||10,901||8,001|
|Total operating expenses||51,014||37,197|
|Loss from operations||(47,988||)||(35,775||)|
|Other income, net:|
|Interest income, net||11||7|
|Other income, net||2,353||343|
|Total other income, net||3,788||706|
|Loss before income taxes||(44,200||)||(35,069||)|
|Income tax provision||—||(172||)|
|Net loss per share attributable to ordinary
shareholders—basic and diluted
|Weighted-average ordinary shares used in
computing net loss per share attributable to
ordinary shareholders—basic and diluted
|Other comprehensive income (loss):|
|Foreign currency translation||97||49|
Media and Patient Contact:
Source: Wave Life Sciences